The Insight Partners published latest research study on "Diet Pills Market Forecast to 2028 – COVID-19 Impact and Global Analysis – by Product Type (Prescription, Over the Counter Drugs and Herbal Supplements), Application (Appetite Suppression, Fat Blocking, Metabolism Raising Pills, and Others), Age Group (Teenagers and Adults), and Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies & Drug Stores)", the global diet pills market is expected to grow from $1.13 Billion in 2021 to $2.27 Billion by 2028; it is estimated to grow at a CAGR of 10.4% from 2021 to 2028.
The diet pills market growth is driven by the increase in self-care, the rising problem of obesity, an increase in the elderly population, and a surge in women taking dietary supplements. However, the challenging regulatory environment is expected to restrict the market growth during the forecast period.
Novo Nordisk A/S, Gelesis, VIVUS LLC, Chong's Health Care, GlaxoSmithKline plc., Pfizer Inc. (Arena Pharmaceutical GmbH), Iovate Health Sciences International Inc., Zoller Laboratories, Currax Pharmaceuticals LLC., Teva Pharmaceutical Industries Ltd. are among the key companies operating in the diet pills market. The companies adopt product innovation strategies to meet the evolving customer demands globally, which also permits them to maintain their brand name in the global diet pills market. Also, market players create partnerships, collaborations, and contracts with hospitals, diagnostic centers, and academic & research institutes to provide frozen tissue samples for various studies, which is driving the diet pills market.